Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 08:30 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase...
February 24, 2026 08:00 ET | Source: Ophirex

Ophirex to Supply Marimastat Drug Substance to Liverpool School of Tropical Medicine for Novel Snakebite Treatment Research

Ophirex will supply marimastat to Liverpool School of Tropical Medicine's Centre for Snakebite Research & Interventions’ (CSRI) Ph2 TOCSINS clinical trial.
February 24, 2026 07:15 ET | Source: Novartis Pharma AG

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead...
February 23, 2026 08:30 ET | Source: PharmAla Biotech

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process
February 20, 2026 07:14 ET | Source: Research and Markets

Clinical Trials Market Competitive Landscape Report 2025: Company Strategies, Sustainability Benchmarking, Key Player Developments, and Revenue Forecasts to 2033

Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitive Landscape of the Clinical Trials Market, Including Company Strategies, Sustainability Benchmarking, Key Player Developments, and Revenue...
February 19, 2026 10:14 ET | Source: Research and Markets

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Market Review 2025: Regional, Phase, Sponsor & Enrollment Analysis with G7 & E7 Coverage and Five-Year Trend Review

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's...
February 19, 2026 10:12 ET | Source: Research and Markets

Epidermolysis Bullosa Global Clinical Trials Market Review 2025: Regional, Phase, Sponsor & Enrollment Analysis with G7 & E7 Coverage and Five-Year Trend Review

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Epidermolysis Bullosa - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial...
February 19, 2026 10:11 ET | Source: Research and Markets

Gastroenteritis Global Clinical Trials Market Review 2025: Regional, Phase, Sponsor & Enrollment Analysis with G7 & E7 Coverage and Five-Year Trend Review

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroenteritis - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The clinical trial report offers a...
February 18, 2026 11:29 ET | Source: Research and Markets

Encephalitis Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Encephalitis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides top line...
February 18, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was...